Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11193240 | 1.00 | GABRR1 (0.46) | GABRR1CYP1A2TP53FOLH1NAALAD2 | |
| SCHEMBL16626924 | 1.00 | GABRR1 (0.46) | GABRR1CYP1A2TP53FOLH1NAALAD2 | |
| SCHEMBL5518553 | 1.00 | GABRR1 (0.46) | GABRR1CYP1A2TP53FOLH1NAALAD2 | |
| SCHEMBL13825268 | 0.87 | — | — | |
| SCHEMBL7110047 | 0.87 | — | — | |
| SCHEMBL12434857 | 0.86 | SLC7A5 (0.46) | GABRR1ENPEP | |
| SCHEMBL15984957 | 0.86 | SLC7A5 (0.46) | GABRR1ENPEP | |
| SCHEMBL13026596 | 0.86 | SLC7A5 (0.46) | GABRR1ENPEP | |
| SCHEMBL12293187 | 0.86 | GABRR1 (0.37) | GABRR1CYP1A2TP53FOLH1NAALAD2 | |
| SCHEMBL20088918 | 0.86 | ACE2 (0.38) | GABRR1CYP1A2FOLH1NAALAD2ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127080-A1 | NOVEL CATIONIC LIPID HAVING CYSTINE SKELETON | NOF CORPORATION (JP) | 2023-04-27 | — | — | US | disclosed |
| US-9562033-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-02-07 | — | — | US | disclosed |
| US-9562033-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-02-07 | — | — | US | disclosed |
| US-20160039783-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2016-02-11 | — | — | US | disclosed |
| US-20160039783-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2016-02-11 | — | — | US | disclosed |
| US-6696234-B2 | Silver halide photosensitive material and isothiazolidine-3-one derivative | FUJI PHOTO FILM CO., LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| US-20030190566-A1 | Silver halide photosensitive material and isothiazolidine-3-one derivative | FUJI PHOTO FILM CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-4595675-A | Hypotensive agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-06-17 | — | — | US | disclosed |
| US-4459158-A | THIOALKANOIC ACID DERIVATIVES | PHILLIPS PETROLEUM COMPANY (US) | 1984-07-10 | — | — | US | disclosed |
| US-4410542-A | HYPOTENSIVE AGENTS, PYRROLINE-1,2-DICARBOXYLIC ACID DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1983-10-18 | — | — | US | disclosed |
| US-4347371-A | HYPERTENSIVE AGENTS; ANTIDIABETIC AGENTS; VISION DEFECTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1982-08-31 | — | — | US | disclosed |
| EP-0056066-A1 | Process for the preparation of a polythiol polymer, sealant composition and sealant | PHILLIPS PETROLEUM COMPANY (US) | 1982-07-21 | — | — | EP | disclosed |
| US-4267307-A | NONTACKY SURFACES BY CURING A POLYOXYALKYLENE GLYCOL WITH END GROUPS CONTAINING PRIMARY HYDROXYL GROUPS MODIFIED BY A MERCAPTO ACID OR ESTER | PHILLIPS PETROLEUM COMPANY (US) | 1981-05-12 | — | — | US | disclosed |
| US-4154840-A | Antihypertensive pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4105776-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127080-A1 | NOVEL CATIONIC LIPID HAVING CYSTINE SKELETON | SGMS1, SLC7A11, SGMS2 | GABRR1 4654/4885CYP1A2 4419/4885TP53 4182/4885 |
| US-20030190566-A1 | Silver halide photosensitive material and isothiazolidine-3-one derivative | NRP1, NR2E3, SCN1B | GABRR1 2087/4885CYP1A2 890/4885TP53 2263/4885 |
| US-20160039783-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | POLRMT, MAVS, EIF2AK2 | GABRR1 2755/4885CYP1A2 3866/4885TP53 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.